BÜHLMANN Quantum Blue®
Therapeutic Drug Monitoring

References

  “Quantum Blue Infliximab assay enables the quantitative determination of the infliximab trough level in serum with a time to result of only 15 minutes and exhibits an excellent correlation with existing ELISAs”
  “The Quantum Blue IFX assay can successfully replace the commonly used ELISA-based IFX quantification kits. This point-of-care IFX assay is able to deliver the results within 15 minutes makes it ideal for an immediate target concentration adjusted dosing. Moreover, it is a user-friendly desktop device that does not require specific laboratory facilities or highly specialised personnel”
  “using the rapid IFX assessment system with a 3µg/ml threshold is a reliable alternative to the time consuming ELISA assays in patients on the maintenance phase of IFX”
  “The Quantum Blue adalimumab test enables the quantitative determination of adalimumab levels from 1 to 35µg/ml in serum with a time to result of only 15 minutes”
  “The QB kit has the added advantage of being a bedside point-of-care solution, releasing results within 15 min of sampling, and therefore allowing an immediate adjustment of CT-P13 dosing”
  “The developed assay allows to measure adalimumab over a wide range. Hence it represents a valuable tool for the clinicians to assess the adalimumab trough level”
- Fellay B et al. ECCO 2018. Quantum Blue Infliximab POC user performance evaluation. Quantum Blue infliximab POC system which determines infliximab levels in serum specimens, is easy-to-use, the given instructions are comprehensive, and the results are comparable between different POC sites as well as between POC sites and laboratories”
  “Using POC testing for IFX patients with a secondary LOR is clinically useful, correlates well with standardized testing, allows for immediate appropriate management of patients and results in a rapid clinical remission as early as 4 weeks”
“This rapid test strategy has the potential to reduce patient risks and improve patient outcomes without negative cost implications”

Strik. A et al. ECCO 2018. Validation of the Quantum Blue Infliximab level rapid test in clinical practice of patients with inflammatory bowel disease.
“It is a good alternative for the conventional ELISA method for the measurement of IFX serum concentrations at trough in IBD patients receiving IFX maintenance treatment”

Use in clinic:
“the test can accurately be performed by a nurse which means that TDM now can be moved from a distant laboratory to the near patient facility like the infusion centre and ensure correct dosing in IBD and other patients on IFX treatment”

“POC IFX-TL measurement was easy to implement on a daily clinical practice setting. IFX-TL considered to be within the therapeutic range were found in one-third of patients. In the remaining patients an immediate treatment adjustment could have been made allowing for resource saving”

Use with Biosimilars:
“POC IFX assay revealed an excellent average spiking recovery percentage 102%”

“The tested assays can be safely used to monitor drug levels in patients medicated with IFX biosimilar SB2”